Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal

 
• By Alaric DeArment
  
Digital illustration of Cancer cell in colour background
Agenus said it would withdraw the BLA for its PD-1 inhibitor, balstilimab, in 2L cervical cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer